56
Participants
Start Date
September 2, 2022
Primary Completion Date
December 14, 2023
Study Completion Date
April 14, 2024
ZT002
"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
Placebo
"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
RECRUITING
Q-Pharm Pty Limited, Herston
Collaborators (1)
Novotech (Australia) Pty Limited
INDUSTRY
Beijing QL Biopharmaceutical Co.,Ltd
INDUSTRY
QL Biopharmaceutical Australia Pty Ltd
INDUSTRY